This study evaluates patients with pretreated HER2-positive or HER2-low advanced BC with stable, untreated, or progressing BMs, and/or leptomeningeal carcinomatosis, allocated into five cohorts based on HER2 expression and metastatic brain status. Here, ERBB2 is linked to breast cancer.